Quick Takeaways
- Brii Biosciences Ltd filed SCHEDULE 13G/A for AN2 THERAPEUTICS, INC. Common Stock, $0.00001 par value per share (ANTX).
- Disclosed ownership: 3.1%.
- Date of event: 31 Dec 2024.
Brii Biosciences Ltd - 31 Dec 2024 SCHEDULE 13G/A Report for AN2 THERAPEUTICS, INC. Common Stock, $0.00001 par value per share (ANTX)
- Filing Manager
- Brii Biosciences Ltd
- Reporting Manager
- Brii Biosciences Limited
- Symbol
- ANTX
- Shares outstanding
- 29,909,710 shares
- Disclosed Ownership
- 927,201 shares
- Ownership
- 3.1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 16:30:17 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Brii Biosciences Ltd disclosed 3.1% ownership in AN2 THERAPEUTICS, INC. Common Stock, $0.00001 par value per share (ANTX) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 16:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Brii Biosciences Limited | 3.1% | 927,201 | 927,201 | 0 | /s/ Ankang Li | Ankang Li, Executive Director, Chief Strategy and Financial Officer |